Valuation: MannKind Corporation

Market Cap 1.3B 1.14B 1.05B 975M 1.85B 124B 1.88B 12.61B 4.9B 61.07B 4.89B 4.79B 211B P/E 2026 *
-134x
P/E 2027 * 29.6x
Enterprise Value 1.3B 1.14B 1.05B 975M 1.85B 124B 1.88B 12.61B 4.9B 61.07B 4.89B 4.79B 211B EV / Sales 2026 *
2.82x
EV / Sales 2027 * 2.5x
Free-Float
98.45%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: MannKind Corporation

1 day-1.17%
1 week-0.94%
Current month-0.94%
1 month+24.12%
3 months+64.20%
6 months-27.86%
Current year-25.57%
1 week 4.08
Extreme 4.08
4.55
1 month 3.41
Extreme 3.41
4.55
Current year 2.23
Extreme 2.23
6.51
1 year 2.23
Extreme 2.23
6.51
3 years 2.23
Extreme 2.23
7.63
5 years 2.23
Extreme 2.23
7.63
10 years 0.67
Extreme 0.6662
7.63
Manager TitleAgeSince
Chief Executive Officer 49 2017-05-24
Director of Finance/CFO 50 2024-04-21
Chief Tech/Sci/R&D Officer 59 2022-09-30
Director TitleAgeSince
Director/Board Member 57 2018-11-26
Director/Board Member 71 2019-12-31
Director/Board Member 82 2003-09-30
Date Insider Type Main position Quantity % Market Cap.
05-19Free

Director

99,337 0.0322%
05-19Free

Director

82,781 0.0268%
05-19Other

Director

82,781 0.0268%
Change 5-day change 1-year change 3-year change Capi.($)
-1.17%-0.94%+19.21%+7.93% 1.32B
-0.10%+0.10%+74.33%+133.26% 57.73B
-3.80%-6.24%+67.04%+86.36% 54.69B
+0.38%+1.33%-14.32%-11.76% 23.75B
+1.17%+5.83%+16.39%+468.18% 24.18B
-2.70%+4.25%+40.38%-3.72% 19.82B
+3.78%+5.65%+44.99%-26.23% 17.14B
+3.46%+17.72%+206.66%+364.07% 16.75B
-1.81%+18.00%+41.99% - 15.57B
+2.79%+4.91%+29.26%+195.60% 13.96B
Average +0.20%+5.22%+52.59%+134.85% 24.49B
Weighted average by Cap. -0.40%+3.35%+57.72%+138.54%

Financials

2026 *2027 *
Net sales 462M 404M 372M 345M 655M 43.83B 666M 4.47B 1.74B 21.63B 1.73B 1.7B 74.76B 521M 456M 420M 389M 739M 49.45B 751M 5.04B 1.96B 24.4B 1.96B 1.91B 84.35B
Net income -501K -439K -404K -375K -712K -47.59M -723K -4.85M -1.89M -23.49M -1.88M -1.84M -81.18M 56.85M 49.75M 45.85M 42.5M 80.67M 5.4B 81.97M 550M 214M 2.66B 213M 209M 9.2B
Net Debt - -
Logo MannKind Corporation
MannKind Corporation is a biopharmaceutical company engaged in transforming chronic disease care through patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, it develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. Its commercial assets include Afrezza, FUROSCIX and V-Go along with Tyvaso DPI. Its commercializing Afrezza (insulin human) Inhalation Powder, an ultra-rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease product, Tyvaso DPI (treprostinil) inhalation powder, is used in the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Employees
592
Date Price Change Volume
26-07-07 US$4.220 -1.17% 3,386,393
26-07-06 US$4.270 -5.53% 4,082,954
26-07-02 US$4.520 +11.60% 9,573,416
26-07-01 US$4.050 -4.93% 2,722,590
26-06-30 US$4.260 +0.47% 6,822,023
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
4.220USD
Average target price
7.594USD
Spread / Average Target
+79.95%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MNKD Stock